Tech Company Financing Transactions
Icosavax Funding Round
Icosavax, based in Seattle, raised $51 million from Qiming Ventures, Adams Street Partners and NanoDimension.
Transaction Overview
Company Name
Announced On
10/4/2019
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Qiming Ventures (Lead Investor) (Mark McDade)
Proceeds Purpose
The proceeds of the financing will be used to advance the company's first vaccine candidate, IVX-121, for respiratory syncytial virus (RSV) for older adults through Phase 1b clinical studies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2815 Eastlake Ave. E 300
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
We are committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. We were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Simpson
Chief Medical Officer
Niranjan Kanesa-thasan
Chief Scientific Officer
Douglas Holtzman
VP - Operations
Charles Richardson
Browse more venture capital transactions:
Prev: 10/4/2019: AmacaThera venture capital transaction
Next: 10/4/2019: Unqork venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs